These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 10065260)

  • 1. [Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].
    Dieleman JP; Hillebrand-Haverkort ME; van der Ende ME; Sturkenboom MC; Lange JM; Stricker BH
    Ned Tijdschr Geneeskd; 1998 Dec; 142(52):2856-60. PubMed ID: 10065260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buffalo hump: what the experts suggest.
    Piliero PJ; McComsey GA
    AIDS Clin Care; 2004 Mar; 16(3):22-3. PubMed ID: 15119294
    [No Abstract]   [Full Text] [Related]  

  • 3. ["Buffalo hump" related to indinavir treatment].
    Dornier C; Posth M; Granel F; Barbaud A; Schmutz JL
    Ann Dermatol Venereol; 1999 Oct; 126(10):720-2. PubMed ID: 10604014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous side effects induced by indinavir.
    Calista D; Boschini A
    Eur J Dermatol; 2000 Jun; 10(4):292-6. PubMed ID: 10846257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.
    Temple ME; Koranyi KI; Nahata MC
    Ann Pharmacother; 2003 Sep; 37(9):1214-8. PubMed ID: 12921501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV protease inhibitor-related lipodystrophy syndrome.
    Carr A
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S135-42. PubMed ID: 10860898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.
    Coplan PM; Cook JR; Carides GW; Heyse JF; Wu AW; Hammer SM; Nguyen BY; Meibohm AR; DiNubile MJ;
    Clin Infect Dis; 2004 Aug; 39(3):426-33. PubMed ID: 15307012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of HIV-associated lipodystrophy.
    Wanke C
    AIDS Clin Care; 2000 Dec; 12(12):100. PubMed ID: 12211161
    [No Abstract]   [Full Text] [Related]  

  • 11. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
    Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
    AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).
    Vigouroux C; Gharakhanian S; Salhi Y; Nguyen TH; Chevenne D; Capeau J; Rozenbaum W
    Diabetes Metab; 1999 Sep; 25(3):225-32. PubMed ID: 10499191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in body shape and metabolic abnormalities.
    Res Initiat Treat Action; 1999 Jan; 5(1):18. PubMed ID: 11366225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipodystrophy.
    Proj Inf Perspect; 1999 Apr; (27):14-5. PubMed ID: 11366731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential gene expression indicates that 'buffalo hump' is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy.
    Guallar JP; Gallego-Escuredo JM; Domingo JC; Alegre M; Fontdevila J; Martínez E; Hammond EL; Domingo P; Giralt M; Villarroya F
    AIDS; 2008 Mar; 22(5):575-84. PubMed ID: 18316998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
    Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on lipodystrophy.
    Gaucher M
    Posit Dir News; 1999; 11(1):20-2. PubMed ID: 11366100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ["Buffalo neck": an unintended secondary effect of treatment with anti-HIV protease inhibitors].
    Milpied-Homsi B; Krempf M; Gueglio B; Raffi F; Stalder JF
    Ann Dermatol Venereol; 1999 Mar; 126(3):254-6. PubMed ID: 10394440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sex and race on lipodystrophy pathogenesis.
    Nolan D; Mallal S
    J HIV Ther; 2001 May; 6(2):32-6. PubMed ID: 11501201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.